Published in Lancet on February 24, 2001
Aftercare for patients with transplanted organs. Dtsch Arztebl Int (2009) 1.72
Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis. World J Gastroenterol (2014) 1.40
Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer's disease. Lancet (2001) 1.14
Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. Clin Transplant (2013) 1.02
Overcoming immunological barriers in regenerative medicine. Nat Biotechnol (2014) 1.02
Overview of immunosuppression in liver transplantation. World J Gastroenterol (2009) 0.96
Current concepts and perspectives of immunosuppression in organ transplantation. Langenbecks Arch Surg (2007) 0.94
Long-term medical management of the liver transplant recipient: what the primary care physician needs to know. Mayo Clin Proc (2012) 0.86
Current status of immunosuppression in liver transplantation. J Clin Exp Hepatol (2013) 0.86
A comprehensive review of immunosuppression used for liver transplantation. J Transplant (2009) 0.86
Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One (2011) 0.83
Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem. World J Gastroenterol (2014) 0.83
Renal impairment after liver transplantation - a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation. Eur J Med Res (2009) 0.82
Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner. Nat Clin Pract Gastroenterol Hepatol (2008) 0.81
Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction. Dig Dis Sci (2010) 0.79
Developments in liver transplantation. Gut (2004) 0.79
Management of immunosuppressant agents following liver transplantation: Less is more. World J Hepatol (2016) 0.78
A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. BMC Surg (2010) 0.78
Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepat Med (2010) 0.78
The challenge of renal function in heart transplant children. Pediatr Nephrol (2006) 0.76
Clinical mycophenolic acid monitoring in liver transplant recipients. World J Gastroenterol (2014) 0.76
Caerulomycin A suppresses immunity by inhibiting T cell activity. PLoS One (2014) 0.76
Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients. Hepat Med (2011) 0.75
Evidence for the immunosuppressive potential of calcineurin inhibitor-sparing regimens in liver transplant recipients with impaired renal function. J Transplant (2011) 0.75
Outcomes of liver transplantation in patients with hepatorenal syndrome. World J Hepatol (2016) 0.75
Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells. Sci Rep (2017) 0.75
Immunosuppressant substitutes in liver transplantation. Lancet (2001) 0.75
Efficacy and safety of a reduced calcineurin inhibitor dose combined with mycophenolate mofetil in liver transplant patients with chronic renal dysfunction. Oncotarget (2017) 0.75
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med (2001) 7.71
Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med (2000) 4.98
Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1991) 4.50
Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet (1992) 3.33
Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1991) 3.15
Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg (1991) 3.12
Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med (2001) 2.56
Surgical treatment in proximal bile duct cancer. A single-center experience. Ann Surg (1996) 2.54
Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant (2007) 2.46
Regulation of gastric epithelial cell growth by Helicobacter pylori: offdence for a major role of apoptosis. Gastroenterology (1997) 2.39
Isoforms of nitric oxide synthase. Characterization and purification from different cell types. Biochem Pharmacol (1991) 2.34
Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet (2000) 2.26
A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. Am J Transplant (2012) 2.24
Infiltrates in protocol biopsies from renal allografts. Am J Transplant (2007) 2.24
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Aliment Pharmacol Ther (2013) 2.21
Cloned human brain nitric oxide synthase is highly expressed in skeletal muscle. FEBS Lett (1993) 2.14
Endoscopic closure of esophageal intrathoracic leaks: stent versus endoscopic vacuum-assisted closure, a retrospective analysis. Endoscopy (2013) 2.08
A sonographically guided technique for central venous access. AJR Am J Roentgenol (1997) 2.05
Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet (1994) 2.05
[Prospective Epidemiologic Study of Epigastric Discomfort (PRESTO). Ground work and preliminary results]. Dtsch Med Wochenschr (1999) 2.01
Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut (2001) 1.97
Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa. Gut (1999) 1.97
Diagnosis of mycobacterial infections by nucleic acid amplification: 18-month prospective study. J Clin Microbiol (1996) 1.94
Nitric oxide synthase in macula densa regulates glomerular capillary pressure. Proc Natl Acad Sci U S A (1992) 1.93
Mutations of the cystic fibrosis gene, but not cationic trypsinogen gene, are associated with recurrent or chronic idiopathic pancreatitis. Am J Gastroenterol (2000) 1.90
Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol (1998) 1.89
Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat (2008) 1.85
Benign liver tumors: differential diagnosis and indications for surgery. World J Surg (1997) 1.83
Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol (1997) 1.83
Association between fulminant hepatic failure and a strain of GBV virus C. Lancet (1996) 1.82
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol (2010) 1.76
Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut (2002) 1.74
Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy (2006) 1.70
Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. Am J Transplant (2011) 1.69
Influence of cold ischemia time, pretransplant anti-porcine antibodies, and donor/recipient size matching on hyperacute graft rejection after discordant porcine to cynomolgus kidney transplantation. Transplantation (2000) 1.69
Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant (2008) 1.67
CFTR and its key role in in vivo resting and luminal acid-induced duodenal HCO3- secretion. Acta Physiol (Oxf) (2008) 1.65
Phenotype and histological distribution of interstitial dendritic cells in the rat pancreas, liver, heart, and kidney. Transplantation (1984) 1.65
Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J (2003) 1.64
CREB controls LAP/C/EBP beta transcription. Mol Cell Biol (1997) 1.62
Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol (1997) 1.61
Regional distribution of EDRF/NO-synthesizing enzyme(s) in rat brain. Biochem Biophys Res Commun (1990) 1.61
Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. Free Radic Biol Med (2001) 1.60
Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol (2004) 1.60
Endothelial nitric-oxide synthase (type III) is activated and becomes calcium independent upon phosphorylation by cyclic nucleotide-dependent protein kinases. J Biol Chem (2000) 1.55
Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology (1996) 1.53
Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. J Clin Virol (2007) 1.51
Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br J Cancer (2005) 1.51
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
Genetic distinctions between types 1 and 2 autoimmune hepatitis. Am J Gastroenterol (1997) 1.49
Surgical treatment of cholangiocellular carcinoma. World J Surg (1995) 1.47
Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol (1999) 1.47
A mass in the eye. Lancet (2002) 1.46
Cognitive performance in pediatric liver transplant recipients. Am J Transplant (2013) 1.46
Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant (2015) 1.46
Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem (1998) 1.45
Structural organization of the hepatitis B virus minichromosome. J Mol Biol (2001) 1.45
FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant (2006) 1.45
Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy (1996) 1.44
Effects of cyclosporine on human dendritic cell subsets. Transplant Proc (2005) 1.43
The soluble guanylyl cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol (1999) 1.42
Hormone-induced biosynthesis of endothelium-derived relaxing factor/nitric oxide-like material in N1E-115 neuroblastoma cells requires calcium and calmodulin. Mol Pharmacol (1990) 1.41
Colocalization of nitric oxide synthase and NADPH-diaphorase in the myenteric plexus of the rat gut. Neurosci Lett (1992) 1.40
[Diagnosis of autoimmune hepatitis]. Med Klin (Munich) (1999) 1.40
Engineering of a glucose-responsive surrogate cell for insulin replacement therapy of experimental insulin-dependent diabetes. Hum Gene Ther (2000) 1.39
Hemodynamic consequences of porcine kidney xenograft reperfusion in cynomolgus monkeys. Transplantation (2001) 1.39
Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology (2001) 1.38
Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol (1999) 1.38
[Inter-observer reliability in the classification of thoraco-lumbar spinal injuries]. Orthopade (1999) 1.37
Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res (1999) 1.36
Subpopulations of GABAergic neurons in laminae I-III of rat spinal dorsal horn defined by coexistence with classical transmitters, peptides, nitric oxide synthase or parvalbumin. Neuroscience (1994) 1.36
Evaluation of the mobility of adjacent segments after posterior thoracolumbar fixation: a biomechanical study. Eur Spine J (2001) 1.34
Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut (2005) 1.34
The number connection tests A and B: interindividual variability and use for the assessment of early hepatic encephalopathy. J Hepatol (1998) 1.34
Interleukin 6 and liver regeneration. Gut (2000) 1.32
Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol (1999) 1.31
Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol (2001) 1.31
Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation. Mol Cell Biol (2001) 1.31
Complement activation by recombinant adenoviruses. Gene Ther (2001) 1.31
Concanavalin A-induced liver cell damage: activation of intracellular pathways triggered by tumor necrosis factor in mice. Gastroenterology (1998) 1.28
GB virus C/hepatitis G virus infection: a favorable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis (1998) 1.27
Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology (1996) 1.27
Acute-phase response factor, increased binding, and target gene transcription during liver regeneration. Gastroenterology (1996) 1.26
Mitogen stimulation cooperates with telomere shortening to activate DNA damage responses and senescence signaling. Mol Cell Biol (2004) 1.25
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. Z Gastroenterol (2011) 1.24
Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology (1997) 1.24
Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. Hepatology (2000) 1.24